Johnson & Johnson will restart shipments of its Covid-19 vaccine to Europe after the continent’s health agency concluded the benefits outweighed the risks even after it identified a “possible link” between the jab and rare blood clots.
强生公司(Johnson & Johnson)将重启向欧洲交付其新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗，此前欧洲卫生机构得出结论称，即便确认该疫苗与罕见的血栓之间“可能存在关联”，接种该疫苗的益处仍大过风险。
您已阅读7%（352字），剩余93%（4393字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。